loading
전일 마감가:
$9.29
열려 있는:
$9.24
하루 거래량:
118.09K
Relative Volume:
0.15
시가총액:
$686.07M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-4.31%
1개월 성능:
-1.62%
6개월 성능:
-47.76%
1년 성능:
+0.00%
1일 변동 폭
Value
$8.82
$9.385
1주일 범위
Value
$8.48
$9.80
52주 변동 폭
Value
$7.80
$28.09

Bicara Therapeutics Inc Stock (BCAX) Company Profile

Name
명칭
Bicara Therapeutics Inc
Name
전화
617-785-8308
Name
주소
245 MAIN STREET, CAMBRIDGE
Name
직원
0
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
BCAX's Discussions on Twitter

BCAX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BCAX
Bicara Therapeutics Inc
9.125 686.07M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.19 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
544.95 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.27 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
559.17 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.94 28.51B 3.81B -644.79M -669.77M -6.24

Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-23 업그레이드 Wells Fargo Underweight → Equal Weight
2025-04-17 개시 Wells Fargo Underweight
2025-02-06 개시 Wedbush Outperform
2024-12-06 개시 H.C. Wainwright Buy
2024-11-05 개시 Rodman & Renshaw Buy
2024-10-08 개시 Cantor Fitzgerald Overweight
2024-10-08 개시 Morgan Stanley Overweight
2024-10-08 개시 Stifel Buy
2024-10-08 개시 TD Cowen Buy
모두보기

Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스

pulisher
Jun 12, 2025

Bicara Therapeutics Elects New Directors at Annual Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Petri Dish: Scorpion spinout debuts with $177M, Bicara doubles footprint - The Business Journals

Jun 12, 2025
pulisher
Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Relay Therapeutics Strengthens Board with Precision Medicine Expert as Phase 3 Cancer Trial Approaches - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Holdings Raised by Bank of America Corp DE - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Estimates BCAX FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 09, 2025

Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock - Investing.com

Jun 09, 2025
pulisher
Jun 06, 2025

Bicara Therapeutics Expands Boston Headquarters with New Lease - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

25,028 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Nuveen Asset Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Merus Raises $300m After ASCO Success - insights.citeline.com

Jun 04, 2025
pulisher
Jun 03, 2025

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Cantor Fitzgerald maintains overweight rating on Bicara stock By Investing.com - Investing.com India

Jun 03, 2025
pulisher
Jun 03, 2025

Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Cantor Fitzgerald maintains overweight rating on Bicara stock - Investing.com

Jun 03, 2025
pulisher
Jun 02, 2025

Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

Stifel reiterates Buy rating on Bicara Therapeutics stock - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Stifel reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com Canada

Jun 02, 2025
pulisher
Jun 02, 2025

Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

Bicara Responds to Rival Merus With Early Survival Data at #ASCO25 - BioSpace

Jun 02, 2025
pulisher
Jun 02, 2025

Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Bicara presents promising early-stage data in head and neck cancers - The Business Journals

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - The Manila Times

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Reports Promising Phase 1/1b Trial Results for Ficerafusp Alfa in HPV-Negative Head and Neck Cancer - Nasdaq

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus ... - Enidnews.com

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses - GlobeNewswire

Jun 01, 2025
pulisher
Jun 01, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewswire Inc.

Jun 01, 2025
pulisher
May 27, 2025

Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients - MSN

May 27, 2025
pulisher
May 27, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Shares Bought by Millennium Management LLC - Defense World

May 27, 2025
pulisher
May 26, 2025

PIZZA PIZZA ROYALTY CORP. ANNOUNCES MAY DIVIDEND and TIMING OF ANNUAL GENERAL MEETING - The Globe and Mail

May 26, 2025
pulisher
May 25, 2025

159,043 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Northern Trust Corp - Defense World

May 25, 2025
pulisher
May 25, 2025

Bicara Therapeutics (NASDAQ:BCAX) Earns “Outperform” Rating from Wedbush - Defense World

May 25, 2025
pulisher
May 25, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

May 25, 2025
pulisher
May 25, 2025

Bicara Therapeutics (NASDAQ:BCAX) Raised to Equal Weight at Wells Fargo & Company - Defense World

May 25, 2025
pulisher
May 24, 2025

Stifel maintains Bicara stock Buy rating, $48 target post-ASCO - Investing.com Australia

May 24, 2025
pulisher
May 24, 2025

Stifel maintains Bicara stock Buy rating, $48 target post-ASCO By Investing.com - Investing.com Canada

May 24, 2025
pulisher
May 24, 2025

112,476 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Deutsche Bank AG - Defense World

May 24, 2025
pulisher
May 24, 2025

Bicara falls after early-stage trial data for head and neck cancer therapy - MSN

May 24, 2025
pulisher
May 24, 2025

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics - MSN

May 24, 2025

Bicara Therapeutics Inc (BCAX) 재무 분석

Bicara Therapeutics Inc (BCAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Bicara Therapeutics Inc 주식 (BCAX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Meisner Lara
Chief Legal Officer
Jun 16 '25
Sale
10.43
15,829
165,096
0
$20.95
price up icon 1.46%
$36.04
price up icon 0.14%
$21.25
price down icon 0.39%
$98.93
price down icon 1.52%
$108.80
price up icon 2.21%
biotechnology ONC
$244.22
price up icon 0.68%
자본화:     |  볼륨(24시간):